Yonsei Med J.  2015 Jan;56(1):295-299. 10.3349/ymj.2015.56.1.295.

Efficacy of Team-Based Financial Incentives for Smoking Cessation in the Workplace

• Yeo CD
• Lee HY
• Ha JH
• Kang HH
• Kang JY
• Kim SK
• Kim MS
• Moon HS
• Lee SH

• KMID: 2352820
• DOI: http://doi.org/10.3349/ymj.2015.56.1.295

Abstract

Worksite smoking cessation programs offer accessibility of the target population, availability of occupational health support, and the potential for peer pressure and peer support. The purpose of this study was to identify the efficacy of the financial incentives given to various teams in the workplace. St. Paul's Hospital's employees were enrolled. Each team of employees consisted of smoking participants and non-smoking fellow workers from the same department. The financial incentive of 50000 won (about $45) was rewarded to the team for each successful participant-not to individual members-after the first week and then after one month. If the smokers in the team remained abstinent for a longer time period, the team was given an incentive of 100000 won for each successful participant after 3 and 6 months. A total 28 smoking participants and 6 teams were enrolled. Self-reported abstinence rates validated by urinary cotinine test at 3, 6, and 12 months after the initial cessation were 61%, 54%, and 50%, respectively. Smokers with high nicotine dependence scores or those who began participation 1 month after enrollment initiation had a lower abstinence rate at 3 months, but not at 6 and 12 months. Participants who succeeded at smoking cessation at 12 months were more likely to be older and have a longer smoking duration history. The financial incentives given to teams could be promising and effective to improve long-term rates of smoking cessation. This approach could use peer pressure and peer support in the workplace over a longer period.

Keyword

Team; incentives; smoking cessation

MeSH Terms

Adult
Demography
Female
Health Promotion/*economics
Humans
Male
*Motivation
Program Evaluation/*methods
Smoking Cessation/*economics
Treatment Outcome
*Workplace

Reference

1. Mokdad AH, Marks JS, Stroup DF, Gerberding JL. Actual causes of death in the United States, 2000. JAMA. 2004; 291:1238–1245.

2. Tamimi A, Serdarevic D, Hanania NA. The effects of cigarette smoke on airway inflammation in asthma and COPD: therapeutic implications. Respir Med. 2012; 106:319–328.

3. Fiore MC, McCarthy DE, Jackson TC, Zehner ME, Jorenby DE, Mielke M, et al. Integrating smoking cessation treatment into primary care: an effectiveness study. Prev Med. 2004; 38:412–420.

4. Volpp KG, Troxel AB, Pauly MV, Glick HA, Puig A, Asch DA, et al. A randomized, controlled trial of financial incentives for smoking cessation. N Engl J Med. 2009; 360:699–709.

5. Stead LF, Buitrago D, Preciado N, Sanchez G, Hartmann-Boyce J, Lancaster T. Physician advice for smoking cessation. Cochrane Database Syst Rev. 2013; 5:CD000165.

6. Stead LF, Lancaster T. Behavioural interventions as adjuncts to pharmacotherapy for smoking cessation. Cochrane Database Syst Rev. 2012; 12:CD009670.

7. Lerman C, Kaufmann V, Rukstalis M, Patterson F, Perkins K, Audrain-McGovern J, et al. Individualizing nicotine replacement therapy for the treatment of tobacco dependence: a randomized trial. Ann Intern Med. 2004; 140:426–433.

8. Nides M, Oncken C, Gonzales D, Rennard S, Watsky EJ, Anziano R, et al. Smoking cessation with varenicline, a selective alpha4beta2 nicotinic receptor partial agonist: results from a 7-week, randomized, placebo- and bupropion-controlled trial with 1-year follow-up. Arch Intern Med. 2006; 166:1561–1568.

9. Zwar NA, Mendelsohn CP, Richmond RL. Supporting smoking cessation. BMJ. 2014; 348:f7535.

10. Smedslund G, Fisher KJ, Boles SM, Lichtenstein E. The effectiveness of workplace smoking cessation programmes: a meta-analysis of recent studies. Tob Control. 2004; 13:197–204.

11. Cahill K, Perera R. Competitions and incentives for smoking cessation. Cochrane Database Syst Rev. 2011; CD004307.

12. Leeks KD, Hopkins DP, Soler RE, Aten A, Chattopadhyay SK;. Worksite-based incentives and competitions to reduce tobacco use. A systematic review. Am J Prev Med. 2010; 38:2 Suppl. S263–S274.

13. Heatherton TF, Kozlowski LT, Frecker RC, Fagerstrm KO. The Fagerstrm Test for Nicotine Dependence: a revision of the Fagerstrm Tolerance Questionnaire. Br J Addict. 1991; 86:1119–1127.

14. West R, Hajek P, Stead L, Stapleton J. Outcome criteria in smoking cessation trials: proposal for a common standard. Addiction. 2005; 100:299–303.

15. Klesges RC, Glasgow RE, Klesges LM, Morray K, Quale R. Competition and relapse prevention training in worksite smoking modification. Health Educ Res. 1987; 2:5–14.

16. Hessol NA. Worksite smoking modification competitions: long-term vs short-term success. Am J Public Health. 1986; 76:819–820.

17. Hennrikus DJ, Jeffery RW, Lando HA, Murray DM, Brelje K, Davidann B, et al. The SUCCESS project: the effect of program format and incentives on participation and cessation in worksite smoking cessation programs. Am J Public Health. 2002; 92:274–279.

18. Gomel M, Oldenburg B, Simpson JM, Owen N. Work-site cardiovascular risk reduction: a randomized trial of health risk assessment, education, counseling, and incentives. Am J Public Health. 1993; 83:1231–1238.

19. Koffman DM, Lee JW, Hopp JW, Emont SL. The impact of including incentives and competition in a workplace smoking cessation program on quit rates. Am J Health Promot. 1998; 13:105–111.

20. Mills EJ, Wu P, Lockhart I, Thorlund K, Puhan M, Ebbert JO. Comparisons of high-dose and combination nicotine replacement therapy, varenicline, and bupropion for smoking cessation: a systematic review and multiple treatment meta-analysis. Ann Med. 2012; 44:588–597.

21. Cahill K, Lancaster T, Green N. Stage-based interventions for smoking cessation. Cochrane Database Syst Rev. 2010; CD004492.

22. Cabezas C, Advani M, Puente D, Rodriguez-Blanco T, Martin C. ISTAPS Study Group. Effectiveness of a stepped primary care smoking cessation intervention: cluster randomized clinical trial (ISTAPS study). Addiction. 2011; 106:1696–1706.

23. Fagerstrm K, Russ C, Yu CR, Yunis C, Foulds J. The Fagerstrm Test for Nicotine Dependence as a predictor of smoking abstinence: a pooled analysis of varenicline clinical trial data. Nicotine Tob Res. 2012; 14:1467–1473.

24. Tillgren P, Haglund BJ, Lundberg M, Romelsj A. The sociodemographic pattern of tobacco cessation in the 1980s: results from a panel study of living condition surveys in Sweden. J Epidemiol Community Health. 1996; 50:625–630.

25. Jhun HJ, Seo HG. The stages of change in smoking cessation in a representative sample of Korean adult smokers. J Korean Med Sci. 2006; 21:843–848.

26. Raherison C, Marjary A, Valpromy B, Prevot S, Fossoux H, Taytard A. Evaluation of smoking cessation success in adults. Respir Med. 2005; 99:1303–1310.

27. Yan J, Xiao S, Ouyang D, Jiang D, He C, Yi S. Smoking behavior, knowledge, attitudes and practice among health care providers in Changsha city, China. Nicotine Tob Res. 2008; 10:737–744.